University of Groningen

Medication safety in patients with cirrhosis

Weersink, Rianne

DOI:
[10.33612/diss.99705129](https://doi.org/10.33612/diss.99705129)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Weersink, R. (2019). *Medication safety in patients with cirrhosis*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen. <https://doi.org/10.33612/diss.99705129>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Medication Safety in **Patients** with **Cirrhosis**

Rianne Antoinet Weersink

Colophon

Financial support for (printing of) this thesis was provided by ZonMw, the Health Base Foundation, the Dutch Digestive Foundation (MLDS), the Dutch Medicines Evaluation Board (CBG-MEB), het Nederlands Bijwerken Fonds, the Groningen Graduate School of Science and Engineering (GSSE), and the University of Groningen and this is gratefully acknowledged.

Cover Design:	Design Your Thesis, www.designyourthesis.com
Layout:	Design Your Thesis, www.designyourthesis.com
Printing:	Ridderprint, www.ridderprint.nl
ISBN (electronic version):	978-94-034-1918-3
ISBN (printed version):	978-94-034-1919-0

© 2019, Rianne A. Weersink.

No part of this thesis may be reproduced or transmitted in any form or in any means without permission of the author. The copyright of previously published chapters of this thesis remains with the publisher.

**rijksuniversiteit
 groningen**

Medication Safety in Patients with Cirrhosis

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

vrijdag 22 november 2019 om 14.30 uur

door

Rianne Antoinet Weersink

geboren op 2 maart 1990
te Tubbergen

Promotor

Prof. dr. K. Taxis

Copromotor

Dr. S.D. Borgsteede

Beoordelingscommissie

Prof. dr. J.G.W. Kosterink

Prof. dr. R.A. de Man

Prof. dr. H.G.M. Leufkens

Table of Contents

1. General introduction	9
<hr/>	
2. Developing practical guidance for safe medication use in patients with cirrhosis	
2.1 Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion	25
2.2 Safe use of proton pump inhibitors in patients with cirrhosis	41
2.3 Altered pharmacokinetics of statins explain increased risk of rhabdomyolysis in advanced cirrhosis	77
2.4 Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis	83
<hr/>	
3. Medication safety in patients with cirrhosis: current practice	
3.1 Prevalence of drug prescriptions and potential safety in patients with cirrhosis: a retrospective real-world study	107
3.2 Medication safety in patients with hepatic impairment: a survey of community pharmacists' knowledge level and their practice in caring for these patients	123
<hr/>	
4. Quality of information from pre- and post-marketing information sources on safe medication use in patients with cirrhosis	
4.1 Evaluation of information in Summaries of Product Characteristics (SmPCs) on the use of a medicine in patients with hepatic impairment	145
4.2 Spontaneous adverse drug reaction reports for patients with cirrhosis: analysis of the nature, quantity and quality of the reports	167
<hr/>	
5. General discussion	173
<hr/>	
Summary	203
Samenvatting	207
Dankwoord	213
List of publications	217
About the author	221